Drugs / VP20621
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01259726 | Jun 2011 → Jun 2013 | Clostridium infectious disease | Shire | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VP20621 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01259726 ↗ |
| Known as | NTCD-M3 | “nontoxigenic C. difficile strain M3 (VP20621; NTCD-M3)” PMID 25942722 ↗ May 2015 |
| Route | Oral | “VP 20621 dosed orally for up to 14 days” NCT01259726 ↗ |